Gamida Cell (NASDAQ: [[ticker:GMDA]]) has appointed Tracey Lodie to serve as its chief scientific officer. She succeeds Tony Peled, who will move to the newly created chief technology officer position. Lodie comes to Gamida Cell from BlueRock Therapeutics, where she was senior vice president, translational immunology. Gamida Cell, which is based in Israel and maintains US operations in Boston, is developing cell therapies for cancer.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
